CN110734472B - 一种具有二肽基肽酶-4抑制活性的寡肽及其应用 - Google Patents
一种具有二肽基肽酶-4抑制活性的寡肽及其应用 Download PDFInfo
- Publication number
- CN110734472B CN110734472B CN201910898353.0A CN201910898353A CN110734472B CN 110734472 B CN110734472 B CN 110734472B CN 201910898353 A CN201910898353 A CN 201910898353A CN 110734472 B CN110734472 B CN 110734472B
- Authority
- CN
- China
- Prior art keywords
- oligopeptide
- dipeptidyl peptidase
- inhibitory activity
- inhibitory
- enzyme
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000015636 Oligopeptides Human genes 0.000 title claims abstract description 61
- 108010038807 Oligopeptides Proteins 0.000 title claims abstract description 61
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 title claims abstract description 47
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 39
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 title claims abstract 13
- 244000269722 Thea sinensis Species 0.000 claims abstract description 37
- 235000013616 tea Nutrition 0.000 claims abstract description 31
- 238000000338 in vitro Methods 0.000 claims abstract description 8
- 235000006468 Thea sinensis Nutrition 0.000 claims abstract description 6
- 235000020279 black tea Nutrition 0.000 claims abstract description 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 21
- 239000000243 solution Substances 0.000 claims description 21
- 102000004190 Enzymes Human genes 0.000 claims description 17
- 108090000790 Enzymes Proteins 0.000 claims description 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 13
- 239000000523 sample Substances 0.000 claims description 12
- 102000004142 Trypsin Human genes 0.000 claims description 10
- 108090000631 Trypsin Proteins 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- 239000012588 trypsin Substances 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 9
- 235000019750 Crude protein Nutrition 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- 239000012488 sample solution Substances 0.000 claims description 6
- 238000000108 ultra-filtration Methods 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 238000004108 freeze drying Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 3
- 238000012512 characterization method Methods 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 238000002955 isolation Methods 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 238000000751 protein extraction Methods 0.000 claims description 3
- 239000007790 solid phase Substances 0.000 claims description 3
- 238000001228 spectrum Methods 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 239000007791 liquid phase Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 1
- 235000013305 food Nutrition 0.000 abstract description 6
- 210000004369 blood Anatomy 0.000 abstract description 5
- 239000008280 blood Substances 0.000 abstract description 5
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 3
- 235000013402 health food Nutrition 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 2
- 208000024891 symptom Diseases 0.000 abstract description 2
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 32
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 150000001413 amino acids Chemical group 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 239000011347 resin Substances 0.000 description 6
- 229920005989 resin Polymers 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 238000001819 mass spectrum Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 4
- 235000011130 ammonium sulphate Nutrition 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000002386 leaching Methods 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 229910021642 ultra pure water Inorganic materials 0.000 description 4
- 239000012498 ultrapure water Substances 0.000 description 4
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 3
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 3
- 102100040918 Pro-glucagon Human genes 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 229960004034 sitagliptin Drugs 0.000 description 3
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- -1 Lys amino acid Chemical class 0.000 description 1
- 239000003875 Wang resin Substances 0.000 description 1
- NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 description 1
- 239000000859 incretin Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/485—Exopeptidases (3.4.11-3.4.19)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
- C12Y304/14005—Dipeptidyl-peptidase IV (3.4.14.5)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明公开了一种具有二肽基肽酶‑4抑制活性的寡肽,寡肽的缩写为QGQELGGALNFK,分子量1458.4Da,所述寡肽的氨基酸序列为Gln‑Gly‑Gln‑Glu‑Leu‑Gly‑Gly‑Ala‑Leu‑Asn‑Phe‑Lys,所述寡肽从黑茶茯砖茶中分离得到,具有实现体外降血糖的效果,可应用于保健食品、特殊医学用途配方食品与生物制药领域,改善糖尿病病人的病症,本发明还公布了所述寡肽的制备方法、含有该寡肽的药品组合物、含有该寡肽的保健品和含有该寡肽的食品。
Description
技术领域
本发明涉及生物制药领域,特别是一种具有二肽基肽酶-4抑制活性的寡肽,本发明还涉及该寡肽的制备方法和应用。
背景技术
胰高血糖素样肽-1(GLP-1)是一种肠促胰岛素,其促进胰岛素分泌作用呈血糖依赖性,可有效维持血糖动态平衡,此外,它还能刺激胰岛B细胞增殖,诱导胰岛B细胞再生,抑制胰岛B细胞凋亡及胰高血糖素的释放,抑制胃肠蠕动,延缓胃排空,降低食欲和食物摄入,增加葡萄糖的利用,改善胰岛素敏感性等,但是GLP-1在体内的半衰期极短,很快就被以二肽基肽酶-4(DPP-4)为主的酶降解,DPP-4抑制剂通过竞争性结合DPP-4的活化部位,降低DPP-4的催化活性,延长体内GLP-1半衰期,从而增加体内GLP-1的量,实现促进胰岛素分泌的目的,DPP-4抑制剂可稳定控制血糖,改善胰岛B细胞功能,而且不会引起患者体质量的增加,并可避免低血糖风险,在用药安全性方面具有显著的优势,被普遍认为是最有希望的治疗2型糖尿病的新药物。
发明内容
本发明旨在提供一种具有二肽基肽酶-4抑制活性的寡肽及其应用。
本发明解决其技术问题所采用的技术方案是:
一种具有二肽基肽酶-4抑制活性的寡肽,所述寡肽的缩写为QGQELGGALNFK,分子量1458.4Da,所述寡肽的氨基酸序列为Gln-Gly-Gln-Glu-Leu-Gly-Gly-Ala-Leu-Asn-Phe-Lys。
所述寡肽从黑茶茯砖茶中分离得到,具体包括如下步骤:
(1)茶蛋白提取:将茯砖茶叶粉碎后过20-40目筛,以料液比为1:5-40的比例混合茶粉和超纯水,于95℃加热浸提10-60min,浸提液过滤后在25℃,8000rpm/min的条件下离心20min,收集上清液,往上清液中加入饱和硫酸铵溶液(上清液:硫酸铵=1:2-6),在4℃静置12h,使蛋白质沉淀,然后,于4℃,6000rpm/min条件下离心20min,取沉淀,用超纯水溶解,在室温中透析24小时,以去除硫酸铵等小分子物质,获得茯砖茶粗蛋白;
(2)粗蛋白的酶解:将步骤(1)制得的茯砖茶粗蛋白样品制成2-10mg/mL的溶液,于50℃水浴中保持10min,用浓度为2.0mol/L的氢氧化钠调节PH至8.0,以酶/底物比(E/S)为1-5%(w/w)的比例添加胰蛋白酶,酶解时间为5-10h,酶解过程中用浓度为2.0mol/L的氢氧化钠溶液调节酸碱度,使其保持在pH 8.0,酶解完成后把样品置于95℃下加热20min使酶灭活,并于4℃,8000rpm/min离心10min,弃去沉淀,制得茯砖茶胰蛋白酶酶解组分,冻干备用;
(3)“酶-抑制肽”复合物的制备:取茯砖茶胰蛋白酶酶解组分配成1-5mg/mL样品溶液,取样品溶液100μL与试剂盒中的二肽基肽酶-4(DPP-4)溶液100μL混合,于37℃下,摇床培养15min,使酶与抑制剂样品充分结合;
(4)未与酶结合成分的去除:培养结束后,把步骤(3)制得的混合物加入截留分子量为30kDa的超滤离心管中,并于常温下,10000rpm/min离心25min,去除样品中未与酶结合的成分,用200μL磷酸缓冲洗截留后的滤液3次,并于常温下,5000rpm/min离心5min;
(5)抑制肽的释放、分离与鉴定:离心后往上层(即“酶-抑制肽”复合物层)液体中加入100-400μL 50%乙腈水溶液,混合均匀,静置10min之后,在常温下以10000rpm/min离心10分钟,重复2次,合并滤出液,过0.22μm超滤膜,制得茯砖茶超滤液,进行高效液相谱分离,收集合适的峰,即获得所述具有二肽基肽酶-4抑制活性的寡肽。
所述寡肽也使用固相合成仪合成制得,也就是说,将目标多肽的C-端羧基以共价键形式与一个不溶性的高分子树脂相连,然后以这个氨基酸的氨基作为起点,与另一分子氨基酸的羧基作用形成肽键,不断重复这一过程,合成反应完成后,去除保护基,将肽链与树脂分离,即得到目标产物。多肽合成是一个重复添加氨基酸的过程,固相合成顺序从C端向N端合成。
一种药物组合物,所述药物组合物含有上述的具有二肽基肽酶-4抑制活性的寡肽。
一种保健品,所述保健品含有上述的具有二肽基肽酶-4抑制活性的寡肽。
一种食品,所述食品含有上述的具有二肽基肽酶-4抑制活性的寡肽。
一种制备上述的具有二肽基肽酶-4抑制活性的寡肽的方法,包括如下步骤:
所述寡肽在浓度为4mg/mL时,对二肽基肽酶-4的体外抑制率为58.2%。
所述寡肽在浓度为10mg/mL时,对二肽基肽酶-4的体外抑制率为66.7%。
所述寡肽对二肽基肽酶-4的50%抑制浓度(IC50)为3.89±0.22mg/mL。
本发明的有益效果是:从茯砖茶中提取了一种具有二肽基肽酶-4抑制活性的寡肽,具有实现体外降血糖的效果,可应用于保健食品、特殊医学用途配方食品与生物制药领域,改善糖尿病病人的病症。
附图说明
下面结合附图和实施例对本发明进一步说明。
图1是实施例1所述茯砖茶超滤液的高效液相色谱图;
图2是实施例1所述寡肽的一级质谱图;
图3是实施例1所述寡肽的二级质谱图;
图4是实施例1所述寡肽的离子碎片分析图;
图5是实施例2所述寡肽的高效液相色谱图;
图6是实施例2所述寡肽的质谱图;
图7是本发明所述寡肽与西格列汀的“浓度-抑制率”折线图。
具体实施方式
实施例1:
一种制备上述的具有二肽基肽酶-4抑制活性的寡肽的方法,包括如下步骤:
(1)茶蛋白提取:将茯砖茶叶粉碎后过20目筛,以料液比为1:20的比例混合茶粉和超纯水,于95℃加热浸提30min,浸提液过滤后在25℃,8000rpm/min的条件下离心20min,收集上清液,往上清液中加入饱和硫酸铵溶液(上清液:硫酸铵=1:4),在4℃静置12h,使蛋白质沉淀,然后,于4℃,6000rpm/min条件下离心20min,取沉淀,用超纯水溶解,在室温中透析24小时,以去除硫酸铵等小分子物质,获得茯砖茶粗蛋白;
(2)粗蛋白的酶解:将步骤(1)制得的茯砖茶粗蛋白样品制成5mg/mL的溶液,于50℃水浴中保持10min,用浓度为2.0mol/L的氢氧化钠调节PH至8.0,以酶/底物比(E/S)为1.5%(w/w)的比例添加胰蛋白酶,酶解时间为6h,酶解过程中用浓度为2.0mol/L的氢氧化钠溶液调节酸碱度,使其保持在pH 8.0,酶解完成后把样品置于95℃下加热20min使酶灭活,并于4℃,8000rpm/min离心10min,弃去沉淀,制得茯砖茶胰蛋白酶酶解组分,冻干备用;
(3)“酶-抑制肽”复合物的制备:取茯砖茶胰蛋白酶酶解组分配成2mg/mL样品溶液,取样品溶液100μL与试剂盒中的二肽基肽酶-4(DPP-4)溶液100μL混合,于37℃下,摇床培养15min,使酶与抑制剂样品充分结合;
(4)未与酶结合成分的去除:培养结束后,把步骤(3)制得的混合物加入截留分子量为30kDa的超滤离心管中,并于常温下,10000rpm/min离心25min,去除样品中未与酶结合的成分,用200μL磷酸缓冲洗截留后的滤液3次,并于常温下,5000rpm/min离心5min;
(5)抑制肽的释放、分离与鉴定:离心后往上层(即“酶-抑制肽”复合物层)液体中加入200μL 50%乙腈水溶液,混合均匀,静置10min之后,在常温下以10000rpm/min离心10分钟,重复2次,合并滤出液,过0.22μm超滤膜,制得茯砖茶超滤液,进行高效液相谱分离。
所用的高效液相色谱仪为Angilent 1100,相关参数设置:A相为水,B相为乙腈,0-2min为85%水,15%乙腈;6-9.5min为15%水,85%乙腈;10-12min为85%水,15%乙腈,流速为0.2mL/min。高效液相色谱分离结果如图1所示,收集第5个峰即获得所述具有二肽基肽酶-4抑制活性的寡肽。
质谱参数设置:ESI离子源,扫描范围50m/z-3000m/z,阳离子模式,端板偏移-500V,电压变化2000V,正离子谱测定,分子量测定范围在500-3000KD。质谱鉴定如图2至图3所示。
实施例2:
采用固相合成仪合成所述具有二肽基肽酶-4抑制活性的寡肽,具体操作为:
(1)通过树脂的筛选合成所述寡肽,选用高分子树脂(王氏树脂,上海阿拉丁生化科技股份有限公司),按照氨基酸序列Gln-Gln-Gly-Gln-Glu-Leu-Gly-Gly-Ala-Leu-Asn-Phe-Lys的特征,先将Gln的羧基以共价键的形式与一个树脂的连接位点相连,然后Gly的氨基和Gln的羧基缩水反应,处理后,再添加Glu,Gln的氨基和Glu的羧基反应,依次从右到左添加氨基酸,加好最后一个Lys氨基酸后,再切除树脂,即得到目标多肽;
(2)采用高效液相色谱进行纯化,色谱柱型号为Phenomenex C18,尺寸4.6*150mm,流动相A:含有0.1%三氟乙酸(TFA)的乙腈;流动相B:含有0.1%TFA的水;25min内B相由95.0%下降到30.0%,流速1.0mL/min,检测波长214nm;
(3)液氮速冻,冷冻干燥,即制得所述具有二肽基肽酶-4抑制活性的寡肽,该成品纯度为95.89%,分子质量为1261.4Da,高效液相色谱分离结果如图5所示,质谱鉴定如图6所示。
对二肽基肽酶-4的体外抑制活性实验:
选取实施例2制得的寡肽分别配成浓度为0.5mg/mL、1mg/mL、1.5mg/mL、2mg/mL、4mg/mL和10mg/mL的寡肽溶液,以二肽基肽酶-4为研究对象,测定寡肽的体外抑制活性。
在黑色96孔板中均加入50μL二肽基肽酶-4酶液,不同的96孔板分别加入各个浓度的25μL寡肽溶液,混合后于37℃摇床反应10min,后加入25μL底物溶液,于37℃摇床反应。
对照组用25μL缓冲液代替25μL寡肽溶液,背景组用50μL缓冲液代替50μL二肽基肽酶-4酶液,阳性对照组分别为25μL相同浓度(即0.5mg/mL、1mg/mL、1.5mg/mL、2mg/mL、4mg/mL和10mg/mL)的西格列汀溶液代替寡肽溶液,其余操作与上述相同。
连续测定加入底物溶液后每个孔15min-30min期间的荧光值(lex=360/lem=460nm),每分钟测定一次。
二肽基肽酶-4的抑制率的计算公式如下:
其中,SlopeEC是对照组的斜率,SlopeSM是实验组的斜率;FLU1和FLU2是曲线上任意两点的荧光值;T1和T2是两点所对应的时间。
对每个孔的数据作“浓度-抑制率”图的线性图象,如图7所示,由图可知所述寡肽对二肽基肽酶-4的50%抑制浓度(IC50)为3.89±0.22mg/mL,同时本发明的寡肽对二肽基肽酶-4的抑制率低于西格列汀,但是对于2型糖尿病的治疗仍有指导意义,可应用于保健食品、特殊医学用途配方食品与生物制药领域,改善糖尿病病人的病症。
实施例3:
一种药物组合物,含有具有二肽基肽酶-4抑制活性的寡肽和药学上可接受的载体或赋形剂,所述寡肽的缩写为QGQELGGALNFK,,氨基酸序列为Gln-Gly-Gln-Glu-Leu-Gly-Gly-Ala-Leu-Asn-Phe-Lys,分子量1458.4Da,所述寡肽从黑茶茯砖茶中分离得到。本实施例为注射剂,主要成分为所述寡肽,其他成分均为制药领域注射剂的常规辅料。
实施例4:
一种保健品,含有具有二肽基肽酶-4抑制活性的寡肽,所述寡肽的缩写为QGQELGGALNFK,分子量1458.4Da,氨基酸序列为Gln-Gly-Gln-Glu-Leu-Gly-Gly-Ala-Leu-Asn-Phe-Lys,所述寡肽从黑茶茯砖茶中分离得到,其他成分均为保健品领域的常规添加材料。
实施例5:
一种食品,含有具有二肽基肽酶-4抑制活性的寡肽,所述寡肽的缩写为QGQELGGALNFK,分子量1458.4Da,氨基酸序列为Gln-Gly-Gln-Glu-Leu-Gly-Gly-Ala-Leu-Asn-Phe-Lys,所述寡肽从黑茶茯砖茶中分离得到,其他成分均是根据食品类型进行添加制作。
以上的实施方式不能限定本发明创造的保护范围,专业技术领域的人员在不脱离本发明创造整体构思的情况下,所做的均等修饰与变化,均仍属于本发明创造涵盖的范围之内。
Claims (6)
1.一种具有二肽基肽酶-4抑制活性的寡肽,其特征在于所述寡肽的缩写为QGQELGGALNFK,所述寡肽的氨基酸序列为Gln-Gly-Gln-Glu-Leu-Gly-Gly-Ala-Leu-Asn-Phe-Lys;
所述寡肽从黑茶茯砖茶中分离得到;
所述寡肽的制备步骤如下:
(1)茶蛋白提取:从茯砖茶叶中提取茯砖茶粗蛋白;
(2)粗蛋白的酶解:将步骤(1)制得的茯砖茶粗蛋白酶解,制得茯砖茶胰蛋白酶酶解组分,冻干备用;
(3)“酶-抑制肽”复合物的制备:取所述茯砖茶胰蛋白酶酶解组分配成1-5mg/mL样品溶液,取样品溶液100μL与试剂盒中的二肽基肽酶-4(DPP-4)溶液100μL混合,于37℃下,摇床培养15min,使酶与抑制剂样品充分结合;
(4)未与酶结合成分的去除:培养结束后,把步骤(3)制得的混合物加入截留分子量为30kDa的超滤离心管中,并于常温下,10000rpm/min离心25min,去除样品中未与酶结合的成分,用200μL磷酸缓冲洗截留后的滤液3次,并于常温下,5000rpm/min离心5min;
(5)抑制肽的释放、分离与鉴定:离心后往上层的“酶-抑制肽”复合物层液体中加入100-400μL 50%乙腈水溶液,混合均匀,静置10min之后,在常温下以10000rpm/min离心10分钟,重复2次,合并滤出液,过0.22μm超滤膜,制得茯砖茶超滤液,进行高效液相谱分离,收集合适的峰,即获得所述具有二肽基肽酶-4抑制活性的寡肽。
2.一种药物组合物,其特征在于所述药物组合物含有权利要求1所述的具有二肽基肽酶-4抑制活性的寡肽。
3.根据权利要求1所述的具有二肽基肽酶-4抑制活性的寡肽,其特征在于所述寡肽使用固相合成仪合成制得。
4.根据权利要求1所述的具有二肽基肽酶-4抑制活性的寡肽,其特征在于所述寡肽在浓度为4mg/mL时,对二肽基肽酶-4的体外抑制率为58.2%。
5.根据权利要求1所述的具有二肽基肽酶-4抑制活性的寡肽,其特征在于所述寡肽在浓度为10mg/mL时,对二肽基肽酶-4的体外抑制率为66.7%。
6.根据权利要求1所述的具有二肽基肽酶-4抑制活性的寡肽,其特征在于所述寡肽对二肽基肽酶-4的50%抑制浓度(IC50)为3.89±0.22mg/mL。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910898353.0A CN110734472B (zh) | 2019-09-23 | 2019-09-23 | 一种具有二肽基肽酶-4抑制活性的寡肽及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910898353.0A CN110734472B (zh) | 2019-09-23 | 2019-09-23 | 一种具有二肽基肽酶-4抑制活性的寡肽及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110734472A CN110734472A (zh) | 2020-01-31 |
CN110734472B true CN110734472B (zh) | 2021-10-15 |
Family
ID=69269468
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910898353.0A Active CN110734472B (zh) | 2019-09-23 | 2019-09-23 | 一种具有二肽基肽酶-4抑制活性的寡肽及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110734472B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111592583B (zh) * | 2020-06-11 | 2022-09-06 | 湖南科技大学 | 一种生物活性多肽及其在制备二肽基肽酶4抑制剂中的应用 |
CN114133431B (zh) * | 2021-12-07 | 2023-07-25 | 昆明理工大学 | 一种马乳源小分子肽及其应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106905416A (zh) * | 2017-04-24 | 2017-06-30 | 南京中医药大学 | 具有抑制二肽基肽酶‑4的活性肽及其制备方法与应用 |
CN106905417A (zh) * | 2017-04-24 | 2017-06-30 | 南京中医药大学 | 一种二肽基肽酶‑4抑制肽及其制备方法与其应用 |
CN107475162A (zh) * | 2017-09-25 | 2017-12-15 | 中国农业科学院农产品加工研究所 | 具有二肽基肽酶‑iv高抑制活性的鼠李糖乳杆菌及其应用 |
-
2019
- 2019-09-23 CN CN201910898353.0A patent/CN110734472B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106905416A (zh) * | 2017-04-24 | 2017-06-30 | 南京中医药大学 | 具有抑制二肽基肽酶‑4的活性肽及其制备方法与应用 |
CN106905417A (zh) * | 2017-04-24 | 2017-06-30 | 南京中医药大学 | 一种二肽基肽酶‑4抑制肽及其制备方法与其应用 |
CN107475162A (zh) * | 2017-09-25 | 2017-12-15 | 中国农业科学院农产品加工研究所 | 具有二肽基肽酶‑iv高抑制活性的鼠李糖乳杆菌及其应用 |
Non-Patent Citations (1)
Title |
---|
In vitro assessment of anti-diabetic potential of 4 kinds of dark tea (Camellia sinensis L.) protein hydrolysates;Keying Su et al.,;《Journal of Applied Botany and Food Quality》;20190128;第92卷;57-63 * |
Also Published As
Publication number | Publication date |
---|---|
CN110734472A (zh) | 2020-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2012237899B2 (en) | Site-directed mono-substituted PEGylated Exendin analog and preparation method therefor | |
CN102766204B (zh) | 胰高血糖素样肽-1突变体多肽及其制备方法和其应用 | |
EA020019B1 (ru) | Аналоги глюкозозависимого инсулинотропного полипептида | |
EA020018B1 (ru) | Процессированные аналоги глюкозозависимого инсулинотропного полипептида | |
AU2015349890A1 (en) | Insulin receptor partial agonists | |
CN102718858A (zh) | 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用 | |
JP2014520798A (ja) | ポリエチレングリコールまたはその誘導体でpeg化されたエキセンジン−4類似体、その調製法、および活性成分としてこれを含有する、糖尿病を予防または処置するための薬学的組成物 | |
CN102363633A (zh) | 胰高血糖素样肽-1突变体多肽及其制备方法、药物组合物和其应用 | |
CN103224558B (zh) | 一种艾塞那肽的制备方法 | |
KR20230018395A (ko) | Glp-1 및 gip 수용체 둘 모두에 대한 이중 작용제 화합물 및 이의 적용 | |
EP4043483A1 (en) | Glp-1 compound | |
EP4036108A1 (en) | Exenatide analog | |
CN110734472B (zh) | 一种具有二肽基肽酶-4抑制活性的寡肽及其应用 | |
CN113135991B (zh) | 一种制备索玛鲁肽的方法 | |
CN107141348A (zh) | 一类长效化艾塞那肽(Exendin-4)类似物及其应用 | |
CN105936647A (zh) | 长效化艾塞那肽(Exendin-4)类似物及其应用 | |
CN107056928A (zh) | 一类长效化胰高血糖素样肽-1(glp-1)类似物及其应用 | |
CN102977204A (zh) | 一种固相合成glp-1类似物的方法 | |
CN102552883B (zh) | 一种多肽复合物、药物组合物、其制备方法和应用 | |
JPH02502636A (ja) | 新規なカルジオジラチン断片およびその製造方法 | |
US7834142B2 (en) | Shortened glucagon-like peptide 1(sGLP-1) preparation method and application | |
CN102532303A (zh) | 聚乙二醇缀合的艾塞那肽的合成及应用 | |
CN110734475B (zh) | 一种具有α-葡萄糖苷酶抑制活性的寡肽及其应用 | |
CN105968186B (zh) | 具有长效化作用的胰高血糖素(Glu)类似物及其应用 | |
CN110128526A (zh) | 长效化艾塞那肽衍生物及其盐与制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |